Eric Hyllengren, M.B.A.

Chief Financial Officer, Tenaya Therapeutics, Inc.

In the seat. First published here October 28, 2026; built from records as of October 28, 2026.

Eric Hyllengren, M.B.A. has been Chief Financial Officer of Tenaya Therapeutics, Inc. since July 13, 2026, according to the company's filing of June 29, 2026.¹

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Tenaya Therapeutics, Inc. (TNYA) Biological Products, (No Diagnostic Substances)	Chief Financial Officer	In the seat	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

July 13, 2026effective
Tenaya Therapeutics, Inc. appointed Eric Hyllengren, M.B.A. as Chief Financial Officer, effective July 13, 2026. Profile of Faraz Ali, M.B.A..
On June 29, 2026, Tenaya Therapeutics, Inc. (the “Company”) announced that Eric Hyllengren, M.B.A., will join the Company as Chief Financial Officer on July 13, 2026 (the “Commencement Date”), and in such capacity, will serve as the Company’s […]
[1] Filing by Tenaya Therapeutics, Inc., filed with the SEC on June 29, 2026. Read the filing. The record at CFO Tribune.

Sources

Current report filed with the SEC, Tenaya Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed June 29, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Eric Hyllengren, M.B.A. wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.